drugset / Trial / NCT02539511
Glutamatergic Modulation of Disordered Alcohol Use
Phase 2/3
Completed
50 enrolled
New York State Psychiatric Institute
National Institute on Alcohol Abuse and Alcoholism (NIAAA) · collab
RandomizedParallel-groupQuadruple-blindTreatment
Summary
Alcohol use disorders remain a significant public health problem. The pharmacological facilitation of behavioral treatment represents a promising strategy for addressing disordered drinking. Alcohol use disorders are recognized to be associated with various vulnerabilities that complicate the course of treatment and that may be amenable to glutamate modulators. The purpose of this randomized, double-blind, controlled trial is to test various glutamate modulators in conjunction with motivational enhancement therapy (MET) for alcohol use disorders.
Timeline
- Start
- 2015-07
- Primary completion
- 2017-09
- Completion
- 2017-12
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | CI-581a | Unknown | 0.71 mg/kg | Intravenous |
| Comparator | CI-581b | Unknown | 0.025 mg/kg | Intravenous |